Europe PMC
open access
Sintilimab‑related cystitis/ureteritis in high‑grade endometrial stromal sarcoma: A case report and structured literature review
Immune checkpoint inhibitors (ICIs) are cutting‑edge therapies in cancer treatment; however, they may trigger unique immune‑related adverse events (irAEs). Although irAEs can affect various organs, ICI‑induced cystitis/ureteritis has rarely been reported. We present a 44‑year‑old female patient with
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Observational Prospective Study of Immune Checkpoint Inhibitors for Solid Neoplasms#1045896
- Neoadjuvant Immune Checkpoint Inhibitor Treatment in Urothelial Cancer#907966
- Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients#804759
- Immune Response to Immunotherapy in Lung Cancer: Study of Sputum and Blood Samples#812848
- Neoadjuvant Immunotherapy With Durvalumab and Tremelimumab for Bladder Cancer Patients Ineligible for Cisplatin#180379
Record · ID 784665
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive